CBD LIFE SCIENCES INC - CBDL STOCK NEWS

CBD Life Sciences Inc. (CBDL) announces strategic entry into the CBD equine market, targeting an underserved niche within the $125 million CBD pet care industry. The market is projected to grow at a 40.3% CAGR through 2028. CBDL's equine-specific products offer natural wellness and therapeutic benefits, developed by veterinary experts to address horses' specific needs. The company aims to capitalize on the relatively untapped equine segment, differentiating itself from the crowded household pet sector. CBDL reports achieving 1405.46% growth since early 2024 across various product categories.

CBD Life Sciences Inc. (CBDL) is positioning itself for growth amid potential federal marijuana legalization in the US. The company reported a 1405.46% revenue increase since February 2024, driven by strategic partnerships including Walmart Marketplace presence. CBDL's product line includes the 3000MG Pain Relief Cream and upcoming launches like CBD Horse Paste and Mellow Mornings CBD Coffee Creamer. The company is expanding globally through Alibaba, targeting the projected $70 billion US legal cannabis market by 2028. With public support for legalization at 68%, CBDL aims to capitalize on growing demand for CBD-infused products in wellness and therapeutic segments.

CBD Life Sciences Inc. (CBDL) reports a 1405.46% revenue increase since February 2024, driven by strategic partnerships and product expansion. The company's growth aligns with potential federal marijuana legalization and projected industry growth to $70 billion by 2028. CBDL's product line includes the 3000MG Pain Relief Cream on Walmart Marketplace, upcoming CBD Horse Paste, and Mellow Mornings CBD Coffee Creamer. The company is expanding globally through Alibaba and focusing on both retail and wholesale distribution channels.

CBD Life Sciences, Inc. (OTC PINK:CBDL) has secured approval to sell its 3000MG Pain Relief Cream on Walmart Marketplace, marking a significant milestone in the company's growth strategy. This achievement opens up access to Walmart's vast customer base and positions CBDL for substantial revenue growth in the multibillion-dollar CBD market.

Key points:

• CBDL's revenue has increased by 1405.46% since February 2024
• The global CBD market is projected to reach $47.22 billion by 2028
• CBDL plans to introduce more best-selling products on Walmart Marketplace
• The company's 3000MG Pain Relief Cream offers potent, fast-acting relief for chronic pain
• This partnership is expected to drive significant growth in market share and revenue

CBD Life Sciences, Inc. (CBDL) announces a 1744.00% revenue growth since February 2024, driven by product innovations and strategic expansion. Key developments include:

1. Launch of Mellow Mornings Nano-CBD Coffee Creamer, utilizing nanotechnology to enhance CBD bioavailability.

2. Introduction of CBD Horse Paste, entering the pet care market.

3. Development of a Nutritional Supplement Powder combining mushroom extracts and ashwagandha.

4. Expansion to Walmart Marketplace in August 2024, with plans to join Alibaba's wholesale platform.

5. Strategic partnerships opening new markets and distribution channels.

CEO Lisa Nelson emphasizes continued growth efforts and commitment to shareholder value. CBDL positions itself as a leader in the expanding global CBD market, projected to reach $47 billion by 2028.

CBD Life Sciences (OTC PINK:CBDL) has signed a Memorandum of Understanding (MOU) with a division of the United States Armed Forces, potentially positioning the company for significant growth in the $14.6 billion adaptogens market. CBDL's mushroom supplement drink powder, featuring reishi mushroom, lion's mane, and ashwagandha root extract, aims to optimize mental clarity, physical stamina, and recovery.

The company has already achieved a 1405.46% revenue increase since February 2024. This MOU opens doors to a massive, untapped market for CBDL's nutraceutical solutions. CEO Lisa Nelson emphasized the partnership's potential as a game-changer for the company. The agreement is expected to serve as a major growth catalyst, driving revenue and elevating the brand into new, high-profile markets.

CBD Life Sciences Inc. (OTC PINK:CBDL) announces its expansion strategy targeting Alibaba, the world's largest retail and e-commerce platform. This move aims to offer CBDL's top-selling CBD products to Alibaba's wholesale marketplace, accessing over 1.28 billion annual active consumers and $3 trillion in gross merchandise volume. The expansion is expected to drive exponential revenue growth and global market penetration.

CBDL's entry into Alibaba's platform, which facilitates over $172 billion in cross-border commerce annually, presents an opportunity to capitalize on the growing demand for CBD products globally. The company's flagship products will be available to wholesalers across Asia, Europe, and beyond. This expansion follows CBDL's impressive 1405.46% revenue increase since February 2024 and aligns with the projected growth of the global CBD market, expected to exceed $47 billion by 2028.

CBD Life Sciences, Inc. (CBDL) reports unprecedented growth in 2024, with a 1,405.46% increase in revenue as of February. The company's expansion into Amazon and Walmart Marketplace has led to a 300% growth in online sales. CBDL's product line, including Mellow Mornings nano CBD coffee creamers and fast-acting pain relief cream, has seen strong demand with a 500% increase in unit sales for nano CBD products. The company's partnerships with coffee shops have resulted in a 40% increase in CBD-infused beverage orders.

CBDL is also entering the cannabis market through dispensary partnerships, projecting significant revenue growth. The company reports a 40% increase in gross margins year-over-year and expects 2024 revenues to exceed $10 million. CBDL emphasizes its focus on innovation, strategic market entry, and retail partnerships to drive future growth.

CBD Life Sciences, Inc. (CBDL) has launched a groundbreaking CBD Horse Paste, a veterinarian-designed solution for equine wellness. This first-of-its-kind product addresses physical and psychological challenges in horses, offering relief from muscle stiffness, joint pain, and anxiety. The paste, containing 500mg of premium CBD per syringe, is designed for maximum absorption and easy administration.

The launch positions CBDL to capitalize on the growing global CBD market, projected to reach $47.22 billion by 2028. The company has already seen a 1405.46% revenue increase since February 2024. The equine CBD market is expected to experience significant growth, potentially driving CBDL's future success in the fast-growing CBD industry.